VPHM Share Price

Open 49.98 Change Price %
High 50.01 1 Day -0.01 -0.02
Low 49.96 1 Week 0.00 0.00
Close 49.96 1 Month 0.00 0.00
Volume 4776453 1 Year 0.00 0.00
52 Week High 9.00
52 Week Low 4.05
VPHM Important Levels
Resistance 2 50.01
Resistance 1 49.99
Pivot 49.98
Support 1 49.93
Support 2 49.91
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

ViroPharma Incorporated (NASDAQ: VPHM)

VPHM Technical Analysis 5
As on 23rd Jan 2014 VPHM Share Price closed @ 49.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 34.43 & Strong Buy for SHORT-TERM with Stoploss of 48.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
VPHM Target for November
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
VPHM Other Details
Segment EQ
Market Capital 1670772992.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
VPHM Address
VPHM
N/A
VPHM Latest News
Interactive Technical Analysis Chart ViroPharma Incorporated ( VPHM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ViroPharma Incorporated
VPHM Business Profile
ViroPharma Incorporated (ViroPharma) is an international biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). The Company is also developing VP20621 for the treatment and prevention of CDAD.